The Society of Nuclear Medicine and Medical Imaging (SNMMI) is praising the U.S. Senate for including neuroendocrine tumors (NETs) in the fiscal year 2025 Senate Defense Appropriations report. NETs are diagnosed and treated with nuclear medicine imaging.
The Senate Appropriations Committee released the report on August 8 and listed NETs as an eligible condition for dedicated research funding through the U.S. Department of Defense’s Congressionally Directed Medical Research Program’s (CDMRP’s) Peer Reviewed Cancer Research Program (PRCRP). The committee recommended that $1.3 million be allocated from the CDMRP's PRCRP, according to the SNMMI.
"SNMMI is encouraged with the inclusion of NETs in the PRCRP and will continue to monitor the appropriations process in the House and Senate," it said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
